196 related articles for article (PubMed ID: 32529733)
1. Advancing structured decision-making in drug regulation at the FDA and EMA.
Angelis A; Phillips LD
Br J Clin Pharmacol; 2021 Feb; 87(2):395-405. PubMed ID: 32529733
[TBL] [Abstract][Full Text] [Related]
2. FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals.
Lackey L; Thompson G; Eggers S
Ther Innov Regul Sci; 2021 Jan; 55(1):170-179. PubMed ID: 32779045
[TBL] [Abstract][Full Text] [Related]
3. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
Bujar M; Ferragu S; McAuslane N; Liberti L; Kühler TC
Clin Ther; 2021 May; 43(5):888-905. PubMed ID: 33883070
[TBL] [Abstract][Full Text] [Related]
4. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views.
Tafuri G; Stolk P; Trotta F; Putzeist M; Leufkens HG; Laing RO; De Allegri M
Ann Oncol; 2014 Jan; 25(1):265-9. PubMed ID: 24356637
[TBL] [Abstract][Full Text] [Related]
5. Canadian, European and United States new drug approval times now relatively similar.
Rawson NSB
Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
[TBL] [Abstract][Full Text] [Related]
6. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
7. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
Joppi R; Bertele V; Vannini T; Garattini S; Banzi R
Br J Clin Pharmacol; 2020 Jan; 86(1):170-174. PubMed ID: 31657044
[TBL] [Abstract][Full Text] [Related]
8. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
9. New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis.
Lexchin J
PLoS One; 2023; 18(6):e0286802. PubMed ID: 37319240
[TBL] [Abstract][Full Text] [Related]
10. One hundred years of drug regulation: where do we go from here?
Woosley RL
Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
[TBL] [Abstract][Full Text] [Related]
11. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
12. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
14. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.
Rohr UP; Iovino M; Rudofsky L; Li Q; Juritz S; Gircys A; Wildner O; Bujar M; Bolte C; Dalla Torre di Sanguinetto S; Wolfer A
Clin Transl Sci; 2023 Sep; 16(9):1569-1581. PubMed ID: 37408165
[TBL] [Abstract][Full Text] [Related]
15. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
[TBL] [Abstract][Full Text] [Related]
16. Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA's Benefit-Risk Framework to Calculate Net-Benefit Score and Benefit-Risk Ratio.
Sun S; Heske S; Mercadel M; Wimmer J
Ther Innov Regul Sci; 2021 Jan; 55(1):129-137. PubMed ID: 32643080
[TBL] [Abstract][Full Text] [Related]
17. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
18. Integration of PKPD relationships into benefit-risk analysis.
Bellanti F; van Wijk RC; Danhof M; Della Pasqua O
Br J Clin Pharmacol; 2015 Nov; 80(5):979-91. PubMed ID: 25940398
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
20. The New Drug Lag: EU Lags in Review Times of Monoclonal Antibodies.
Sharma V; Deore VD; Deore SV; Martin IG
Ther Innov Regul Sci; 2020 Jul; 54(4):770-774. PubMed ID: 32557295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
